Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Inc.
Advaxis Applies for Approximately $1.0 Million Worth of Grants from the National Institute of Health
May 13th, 2009
Advaxis, Inc. (OTCBB: ADXS) has met the needed application requirements for approximately $1.0 million worth of grants from the National Institute of Health (NIH) in the development of its Listeria monocytogenes platform. “The current stimulus package has significantly increased funding for NIH grants,” commented Advaxis CEO Thomas A. Moore. “We have been the fortunate recipient of a multitude of NIH grants. We believe the proposals hold great promise.” About Advaxis Vaccines HER-2 Antigen: The Company’s HER-2 vaccine is based upon a chimeric assembly of many internal and external immune epitopes found to be effective anti-cancer targets. Although never before used...
Source: Vaccine Weekly (2009-05-13)
|
